Generic Drug Liability: Harvard Researchers Propose New Adverse Events Database, Compensation Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Jerry Avorn and his colleagues suggest that a new database be created at FDA to be managed by the agency’s Sentinel program, PCORI or another organization; they also recommend development of a “consensus label” and a minimum Rx fee to fund pharmacovigilance.
You may also be interested in...
Supreme Court To Reconsider “Rules Of the Road” In Generic Preemption
Design defect claims made against generic companies are focus of a case involving Mutual Pharmaceutical’s generic sulindac; ruling may eliminate lower court carve-outs to its Mensing decision.
Generics Liability Bill Could Face Uphill Road In Senate
Sen. Leahy plans to introduce legislation to overturn the Supreme Court’s ruling in Pliva v. Mensing; the attorney who represented generic manufacturers in that case says the legislation is unlikely to pass.
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.